Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus KETEK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus KETEK.
COR-OTICIN vs KETEK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Telithromycin binds to the 50S subunit of bacterial ribosome, inhibiting protein synthesis by blocking peptide chain elongation.
1-2 drops in each affected ear twice daily for 7 days.
Telithromycin 800 mg orally once daily for 7-10 days.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal half-life (t½) is 9.8–10.6 hours in young healthy adults, allowing once-daily dosing. In elderly or severe hepatic impairment, t½ may be prolonged.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily fecal (≈70%) via biliary excretion of unchanged drug; renal excretion accounts for ≈13% (mostly unchanged), with additional minor metabolism (<30%).
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic, Ketolide